Document Classification

Section Type: RESULTS

Text: The following results were in favor (statistically significant findings, p less than 0. 05) of nedocromil sodium compared with placebo : all diary card efficacy variables (nighttime asthma, morning tightness, daytime asthma, cough, twice daily peak expiratory flow [PEF], inhaled beta 2 use) during all periods of assessment (weeks 1 to 2, 3 to 4, 5 to 6, and 7 to 8) with the exception of cough and nighttime beta 2 use during weeks 1 to 2 ; patient and clinician opinion of treatment efficacy (end of weeks 4 and 8) ; ability to reduce the theophylline dose ; clinician assessment of asthma severity at the end of the study, and clinic FEV1 at weeks 4, 5, 6, and 8.